GRIT Biotechnology Awarded National High-Tech Enterprise Designation

Nov 21, 2024 08:00 CST Updated 08:00

Grit Biotechnology

Developer of Immunotherapy Drugs for Solid Tumors

Recently, after review and evaluation by the Office of the National Leading Group for the Administration of High-tech Enterprise Recognition,Suzhou Gravel Biotechnology Co., Ltd.Awarded "National High-tech Enterprise"Title!"

"National High-tech Enterprise" is announced by the Leading Group for the Identification and Management of National High-tech Enterprises, jointly established by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation. It is the most authoritative assessment of national high-tech enterprises in China, aiming to focus on the high-tech fields supported by the state, promote the transformation of scientific and technological achievements, form a core cluster of intellectual property rights, and encourage enterprises to firmly follow the path of independent innovation and development.

The criteria for the recognition of high-tech enterprises nationwide are very strict, and the recognition agencies impose rigorous requirements on enterprises.Operating conditions, intellectual property layout, R&D investment, technology transfer, talent structure, etc.Conduct comprehensive evaluations and integrated reviews. Successfully being recognized as a "National High-tech Enterprise" is beneficial for establishing a brand image, enhancing the company's own value, and also makes it easier to gain policy support, tax incentives, attract more investment, and core talent.

The successful selection as a national high-tech enterprise this time,This fully demonstrates the recognition by relevant national departments of Suzhou Gravel Biotechnology Co., Ltd.'s years of efforts in technology research and development, product innovation, and more., which is another milestone honor achieved by Suzhou Gravel Biotechnology Co., Ltd.

About Suzhou Gravel Biotechnology Co., Ltd.

Suzhou Gravel Biotechnology Co., Ltd. was founded in 2019. It is an innovative pharmaceutical company focusing on tumor immunotherapy and cell treatment, with a research and development pipeline represented by TIL drugs. Gravel Biotechnology has completed multiple rounds of equity financing and received support from several well-known venture capital funds both in China and internationally.GT101 Injection, independently developed by Suzhou Gravel Biotechnology Co., Ltd., is the first TIL drug in China to be approved for clinical registration and has now entered a pivotal Phase II clinical trial. GT201 Injection, the world’s first membrane-bound IL-15 complex-engineered TIL product developed by Gravel Biotechnology, has completed dual clinical trial applications in both China and the United States. The company's core R&D platforms include the StemTexp® stem-like TIL expansion technology platform, StaViral® stable viral production system, ImmuT Finder® immunomodulatory target discovery platform, and KOReTIL® high-efficiency gene knockout system. Based on these platforms, Gravel Biotechnology has developed a series of next-generation gene-edited TIL therapeutics. With internationally leading technical expertise and industrial resources, Gravel Biotechnology aims to create groundbreaking cellular therapies for solid tumors, bringing new hope to cancer patients worldwide.